← Back to Search

Remote Monitoring with TDtect for Tardive Dyskinesia

N/A

Recruiting

Research Sponsored by iRxReminder

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Awards & highlights

Study Summary

This trial tests if it's possible to monitor a movement disorder from a distance without an in-person visit.

Who is the study for?

This trial is for English-speaking individuals who have been on antipsychotic medication for at least 90 days. It's not suitable for those with Tardive Dyskinesia symptoms from Parkinson's, Tourette's, or Huntington disease. Participants must consent to the study and cannot have had a severe head injury in the past year, learning disorders that affect protocol adherence, or uncorrectable severe visual impairment.Check my eligibility

What is being tested?

The trial is testing 'TDtect', a method for remotely monitoring and assessing Tardive Dyskinesia—a movement disorder caused by long-term use of certain medications. The goal is to see if this tool can effectively evaluate patients outside of a clinical setting.See study design

What are the potential side effects?

Since 'TDtect' involves remote assessment tools rather than medication or invasive procedures, traditional side effects are not applicable. However, there may be indirect effects related to privacy concerns or data misinterpretation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

AIMS Score

Trial Design

2Treatment groups

Experimental Treatment

Group I: Taking antipsychotic medication without Tardive DyskinesiaExperimental Treatment1 Intervention

Group II: Taking antipsychotic medication with Tardive DyskinesiaExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

iRxReminderLead Sponsor

National Institute of Mental Health (NIMH)NIH

2,786 Previous Clinical Trials

2,689,399 Total Patients Enrolled

Rakesh Ranjan, M.D.Study DirectorCharak Research Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities for individuals to join this investigation?

"Affirmative. The portal on clinicaltrials.gov confirms that this research project, which was posted online in May of 2023, is actively searching for participants. A total of 300 individuals need to be enlisted from two different medical sites."

Answered by AI

What is the current population count of participants undertaking this medical research?

"Yes, this research is still open to new patients. According to clinicaltrials.gov, this study was first posted on May 30th 2023 and the details have since been edited as recently as August 21st of the same year. Approximately 300 participants are needed for enrolment across 2 sites."

Answered by AI

Who else is applying?

What site did they apply to?

Fermata Helath

What portion of applicants met pre-screening criteria?

Met criteria

Why did patients apply to this trial?

I've been on Ingreza with no success. I am currently on the maximum acceptable dosage of Austedo but also take Valium and Ativan multiple times daily to try and keep my movements somewhat controlled. I also get Botox injections in my face, head, and neck every 12 weeks but they wear off about 5 weeks in. There is no stability to my treatment as far as controlling symptoms.

PatientReceived 1 prior treatment

Recent research and studies

clinicaltrials.govStudy

Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

2023. "Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06011408.

All > Tardive Dyskinesia